A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck

Trial Profile

A Blind Randomized Multicenter Study of Accelerated Fractionated Chemo-radiotherapy With or Without the Hypoxic Cell Radiosensitizer Nimorazole (Nimoral), Using a 15-gene Signature for Hypoxia in the Treatment of Squamous Cell Carcinoma of the Head and Neck

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Nimorazole (Primary) ; Cisplatin
  • Indications Head and neck cancer
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 24 Oct 2013 Planned end date changed from 1 Oct 2020 to 1 Dec 2020 as reported by ClinicalTrials.gov.
    • 24 Oct 2013 Planned initiation date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
    • 09 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top